[Role of biomarkers for risk stratification in the tailored follow-up of heart failure patients]
- PMID: 20873464
[Role of biomarkers for risk stratification in the tailored follow-up of heart failure patients]
Abstract
Recent advances in the understanding of the pathophysiology of heart failure have made available among novel diagnostic tools an increasing number of biohumoral markers. In the setting of chronic heart failure, natriuretic peptides and troponins have been proposed for routine clinical use to evaluate functional severity of cardiac damage, for prognostic stratification across the whole spectrum of disease evolution, to assess treatment effectiveness, and to guide therapy. We discuss their clinical significance and role in a tailored strategy for patient follow-up.
Similar articles
-
Old and new biomarkers of heart failure.Eur J Heart Fail. 2009 Apr;11(4):331-5. doi: 10.1093/eurjhf/hfp035. Eur J Heart Fail. 2009. PMID: 19329823 Review.
-
Importance of myocardial damage in acute decompensated heart failure: changing the paradigm from a passive to an active process.Minerva Cardioangiol. 2005 Dec;53(6):523-35. Minerva Cardioangiol. 2005. PMID: 16333236 Review.
-
[Natriuretic peptides in heart failure].G Ital Nefrol. 2006 Jan-Feb;23 Suppl 34:S32-7. G Ital Nefrol. 2006. PMID: 16633992 Review. Italian.
-
[Cardiac biomarkers and pulmonary embolism: prognostic stratification].Rev Med Suisse. 2009 Oct 14;5(221):2022-4, 2026-7. Rev Med Suisse. 2009. PMID: 19911687 French.
-
Combining natriuretic peptides and necrosis markers in determining prognosis in heart failure.Rev Cardiovasc Med. 2003;4 Suppl 4:S20-8. Rev Cardiovasc Med. 2003. PMID: 14564225 Review.